-+ 0.00%
-+ 0.00%
-+ 0.00%

Aclaris' Bosakitug Misses Primary Endpoint in Phase 2 Atopic Dermatitis Trial

PUBT·11/16/2026 08:30:07
Aclaris' Bosakitug Misses Primary Endpoint in Phase 2 Atopic Dermatitis Trial
  • Aclaris Therapeutics reported Phase 2 results today showing bosakitug missed primary and secondary endpoints in moderate-to-severe atopic dermatitis.
  • Bosakitug was generally well tolerated; development priorities remain oral kinase inhibitors and the bispecific antibody ATI-052.
  • A Phase 2b trial of oral ITK/JAK3 inhibitor modzatinib in lichen planus has begun.
  • ATI-9494 completed studies supporting an investigational new drug application, with filing expected this quarter.
  • A Phase 2b trial of ATI-052 in eosinophilic esophagitis is planned for the first quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160328PRIMZONEFULLFEED9877971) on November 16, 2026, and is solely responsible for the information contained therein.